IFN-β treatment has been proposed to treat patients in early stages of COVID-19, especially if applied at the site of infection, while immunomodulatory drugs may help reduce inflammation in patients in late stages of COVID-19 (96). This evidence concerns the gene IFNB1 and COVID-19.